2020-18244. Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Customer/Partner Service Surveys  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, Health and Human Services (HHS).

    ACTION:

    Notice.

    SUMMARY:

    The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

    DATES:

    Submit written comments (including recommendations) on the collection of information by September 21, 2020.

    ADDRESSES:

    To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to https://www.reginfo.gov/​public/​do/​PRAMain. Find this particular information collection by selecting “Currently under Review—Open for Public Comments” or by using the search function. The OMB control number for this information collection is 0910-0360. Also include the FDA docket number found in brackets in the heading of this document.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Ila S. Mizrachi, Office of Operations, Food and Drug Administration, Three White Flint North, 10:00 a.m.-12:00 p.m., 11601 Landsdown St., North Bethesda, MD 20852, 301-796-7726, PRAStaff@fda.hhs.gov.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.Start Printed Page 51450

    Customer/Partner Service Surveys

    OMB Control Number 0910-0360—Extension

    Under section 1003 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 393), FDA is authorized to conduct research and public information programs about regulated products and responsibilities of the Agency. Executive Order 12862, entitled “Setting Customer Service Standard,” directs Federal Agencies that “provide significant services directly to the public” to “survey customers to determine the kind and quality of services they want and their level of satisfaction with existing services.” FDA is seeking extension of an existing OMB clearance to conduct a series of surveys to implement Executive Order 12862. Participation in the surveys is voluntary. This request covers customer/partner service surveys of regulated entities, such as food processors; cosmetic, drug, biologic, and medical device manufacturers; consumers; and health professionals. The request also covers “partner” (State and local governments) customer service surveys.

    FDA will use the information from these surveys to identify strengths and weaknesses in service to customers/partners and to make improvements. The surveys will measure timeliness, appropriateness and accuracy of information, courtesy, and problem resolution in the context of individual programs.

    FDA estimates conducting 15 customer/partner service surveys per year, each requiring an average of 15 minutes for review and completion. We estimate respondents to these surveys to be between 100 and 20,000 customers. Some of these surveys will be repeats of earlier surveys for purposes of monitoring customer/partner service and developing long-term data.

    Respondents to this collection of information cover a broad range of stakeholders who have specific characteristics related to certain products or services regulated by FDA.

    In the Federal Register of January 21, 2020 (85 FR 3389), we published a 60-day notice requesting public comment on the proposed collection of information. No comments were received.

    FDA estimates the burden of this collection of information as follows:

    Table 1—Estimated Annual Reporting Burden 1

    Type of surveyNumber of respondentsNumber of responses per respondentTotal annual responsesAverage burden per responseTotal hours
    Mail, telephone, web-based55,000155,0000.25 (15 minutes)13,750
    1 There are no capital costs or operating and maintenance costs associated with this collection of information.

    Based on a review of the information collection since our last request for OMB approval, we have made no adjustments to our burden estimate.

    Start Signature

    Dated: August 14, 2020.

    Lowell J. Schiller,

    Principal Associate Commissioner for Policy.

    End Signature End Supplemental Information

    [FR Doc. 2020-18244 Filed 8-19-20; 8:45 am]

    BILLING CODE 4164-01-P

Document Information

Published:
08/20/2020
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
2020-18244
Dates:
Submit written comments (including recommendations) on the collection of information by September 21, 2020.
Pages:
51449-51450 (2 pages)
Docket Numbers:
Docket No. FDA-2019-N-6063
PDF File:
2020-18244.pdf